SWOG clinical trial number
CTSU/NRG-BR004
A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Open
Phase
Abbreviated Title
Phase III Double-Blind Trial, of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Status Notes
Temporary Closure - Effective 6/23/21
Activated by NRG Oncology on 3/12/19.
Activated by SWOG: 7/24/2019
Activated by NRG Oncology on 3/12/19.
Activated by SWOG: 7/24/2019
Activated
07/24/2019
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE
Research committees
Breast Cancer
Early Therapeutics & Rare Cancers
Treatment
Trastuzumab
Pertuzumab
Atezolizumab
Paclitaxel
Eligibility Criteria Expand/Collapse
Eligibility criteria are accessible from the protocol abstract page on the CTSU website (http://www.ctsu.org).
Other Clinical Trials
SWOG Clinical Trial Number
S2505
Phase III Randomized Study Testing Non-Inferiority of Short-Course Ultra-Hypofractionated Radiation (UHRT-5) Versus Standard Fractionation (RT-25) for Stage II-IIIB, Extremity, Resectable Soft Tissue Sarcoma
Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
07/06/2026
Open
SWOG Clinical Trial Number
SN2426
A Randomized Phase II Study of Amivantamab (JNJ-61186372) and hyaluronidase (rHuPH20) versus Cetuximab in Immunocompromised Participants with Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma
Research Committee(s)
Early Therapeutics & Rare Cancers
Sarcoma
Activated
01/28/2026
Accrual
9%
Open
Phase
SWOG Clinical Trial Number
CTSU/AOST2032
AOST2032: A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
02/17/2023
Open